Vol. 18/No. 02 | Oncology Live®

January 26, 2017

Charles L. Loprinzi, MD may have landed somewhat accidentally into the world of symptom management research, but once he arrived, he was there to stay.

January 20, 2017

It was little more than 3 years ago that ibrutinib became the first Bruton tyrosine kinase (BTK) inhibitor to gain the FDA’s approval with a second-line indication for patients with mantle cell lymphoma.

January 18, 2017

The power of that ability to analyze cancers over broad populations has generated much excitement in the drug development arena and it’s not hard to understand the reasons.

January 13, 2017

Amid a rising incidence of thyroid cancer, endocrine surgeons have increasingly explored minimally invasive approaches for operating on patients with the disease.

January 13, 2017

The ambitious goals of the Cancer Moonshot initiative, now incorporated into the recently enacted 21st Century Cures Act, are generating excitement among oncology leaders.

January 12, 2017

Researchers are seeking to determine whether adding the PARP inhibitor veliparib to a chemotherapy combination will improve outcomes for patients with HER2-negative, germline BRCA-associated metastatic or locally advanced breast cancer.

January 11, 2017

In 1941, Charles Brenton Huggins, MD, observed that prostate cancer could be controlled by hormone-directed treatments, a discovery for which he was awarded half the Nobel Prize in Physiology or Medicine in 1966.

January 09, 2017

It is perhaps a little unusual that an oncol­ogy commentary would begin with a highly provocative discussion about the future of driverless cars, but there are similarities in the sharp corners of the debate over this new tech­nology and emerging trends in cancer care.